Bio Medica Laboratories SME IPO
ListedNSE SMEOpens 21 May 2026Closes 25 May 2026
Bio Medica Laboratories Limited, incorporated in 2015, is an Indian pharmaceutical manufacturer specializing in parenteral formulations. The company develops and contract-manufactures a wide range of ethical drugs,…
Bio Medica Laboratories Limited, incorporated in 2015, is an Indian pharmaceutical manufacturer specializing in parenteral formulations. The company develops and contract-manufactures a wide range of ethical drugs, generic medicines, and over-the-counter (OTC) products in the form of liquid and dry powder injectables. Operating entirely on a B2B contract manufacturing model, it designs multi-dose and single-dose injectables for both human and veterinary applications. The company runs two specialized production facilities in Indore, Madhya Pradesh, certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).
Show moreShow less
Key ratios
As per RHP / filingsTimeline
IPO Opens
21 May
IPO Closes
25 May
Allotment
26 May
Listing
29 May
IPO Timeline & Listing Details
| Event | Date |
|---|---|
| IPO Open Date | 21 May 2026 |
| IPO Close Date | 25 May 2026 |
| Allotment Date | 26 May 2026 |
| Listing Date | 29 May 2026 |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Individual | 2 | ₹2,78,000 |
SHNI (Min) | 3 | ₹4,17,000 |
SHNI (Max) | 7 | ₹9,73,000 |
BHNIAbove ₹10,00,000 | 8 | ₹11,12,000 |
IPO Reservation Details
| Category | Reservation |
|---|---|
| QIB (Qualified Institutional Buyer) | 1.00% |
| NII (Non-Institutional Investor) | 48.98% |
| SHNI (Small Non-Institutional Investor) | 15.51% |
| BHNI (Big Non-Institutional Investor) | 31.02% |
| Retail | 50.01% |
| Market Maker | 5.01% |
| Total | 100.00% |
IPO Objectives
- Enhancement of its existing production capabilities by setting up a new manufacturing facility at the existing Indore premises (₹28.50 Cr).
- Repayment or prepayment of outstanding loans availed by the company (₹6.50 Cr).
- General Corporate Purposes.
Strengths
- The company has built a Diversified Parenteral Product Stack, featuring a broad formulation pipeline of 58 liquid and 15 dry powder injectable layouts spanning critical antibiotic and pain management therapeutics.
- It operates on a Pure B2B Contract Manufacturing Model, focusing entirely on institutional specialized processing lines that ensure custom specifications and sticky, long-term B2B linkages.
- The business boasts an Excellent Profitability Profile, demonstrating robust operational efficiencies with an impressive PAT Margin of 30.35% and a strong EBITDA margin of 47.11% (as of Nov 2025).
- It maintains Certified Regulatory Standings, operating out of dual production units in Madhya Pradesh backed by regulatory GMP and GLP standard approvals.
- The firm exhibits High Return Ratios, showcasing exceptional pre-IPO operational returns with an outstanding RoNW profile reaching 54.41%.
Weaknesses
- The company carries Significant Financial Leverage, with an aggressive debt burden of ₹38.17 Cr against a net worth of ₹17.12 Cr, driving a high debt-to-equity ratio of 2.23.
- There is a notable Client Concentration Risk, as business metrics rely heavily on strategic procurement agreements with a finite base of pharmaceutical players, leaving it exposed to client churn.
- The issue faces a Flat Initial Premium, with unofficial grey market sentiment sitting flat at ₹0, indicating a highly conservative local market reception ahead of launch.
- It operates with a Highly Constrained QIB Pool, where the QIB reservation is exceptionally small at 1.00%, shifting massive retail and NII dependency onto public absorption.
Financial Performance
| Period Ended | 30 Nov 2025 (8M) | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets (₹ Cr.) | 65.17 | 39.12 | 19.53 | 17.57 |
| Revenue (₹ Cr.) | 28.63 | 38.33 | 15.34 | 16.25 |
| PAT (₹ Cr.) | 8.66 | 9.79 | 2.5 | 0.33 |
| Net Worth (₹ Cr.) | 17.12 | 14.73 | 4.94 | 2.44 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | 8.66 | 13.45 | 54.41% | 17.12 |
| Zenotech Laboratories Limited | 2.89 | 84.31 | -1.13% | 96.76 |
| Shukra Pharmaceuticals Limited | 15.31 | 62.8 | 24.54% | 63.43 |
Subscription Details
Daily Bids Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 15.94x | 15.94x | 15.94x |
| NII | 0.03x | 0.28x | 1.3x |
| S-HNI | 0.06x | 0.46x | 2.19x |
| B-HNI | 0.01x | 0.19x | 0.86x |
| RII | 1.09x | 1.42x | 2.92x |
| Total | 0.72x | 1.01x | 2.26x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 36,000 | 5,74,000 | 7.98 |
| NII | 17,55,000 | 22,86,000 | 31.78 |
| Small NII | 5,85,000 | 12,82,000 | 17.82 |
| Big NII | 11,70,000 | 10,04,000 | 13.96 |
| RII | 17,92,000 | 52,26,000 | 72.64 |
| Total | 35,83,000 | 80,86,000 | 112.4 |
Company Details
- Bio Medica Laboratories Ltd.
- Plot No. 11B-11C, Sector-E, Sanwer Road Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh, 452015
- +91 7314102751
- companysecretary@biomedica.co.in
- https://biomedica.co.in/
Registrar Details
- Skyline Financial Services Pvt.Ltd.
- 02228511022
- ipo@skylinerta.com
- https://www.skylinerta.com/
Frequently Asked Questions
What does Bio Medica Laboratories do?
What are the IPO dates for Bio Medica Laboratories SME IPO?
What is the price band and minimum investment for Bio Medica Laboratories IPO?
What is the Grey Market Premium (GMP) of Bio Medica Laboratories IPO today?
Where will Bio Medica Laboratories IPO be listed?
Bio Medica Laboratories SME IPO News & Updates
Follow the latest updates for Bio Medica Laboratories SME IPO, including grey market moves and allotment news.
Bio Medica Laboratories SME IPO IPO Pages
Open related pages for this IPO: details, GMP, subscription, allotment, review, FAQ, registrar, timeline, and news.
Bio Medica Laboratories SME IPO Details
Issue size, price, financials, and company info
Bio Medica Laboratories SME IPO GMP
Live grey market premium and listing estimate
Bio Medica Laboratories SME IPO Subscription
QIB, NII, Retail, SHNI and BHNI subscription
Bio Medica Laboratories SME IPO Allotment
Allotment date, chances, and check by PAN
Bio Medica Laboratories SME IPO Review
SWOT, strengths, risks, and IPO review
Bio Medica Laboratories SME IPO FAQ
Common questions on dates, GMP, and allotment
Bio Medica Laboratories SME IPO Registrar
Registrar website and how to check allotment
Bio Medica Laboratories SME IPO Timeline
Open, close, allotment, and listing dates
Bio Medica Laboratories SME IPO News
Updates, blogs, and latest IPO news
Sources
We match Bio Medica Laboratories SME IPO IPO numbers with official sources. For final dates and allotment results, double-check the registrar or exchange.
- SEBIRules for IPO allotment and disclosures in India
- NSEExchange notices, bidding data, and listing updates
- BSEExchange notices and IPO allotment check tools
- RHP / Offer DocumentCheck the company RHP on NSE/BSE or the IPO detail page
- Skyline Financial Services Pvt.Ltd.Official site to check allotment status for this IPO
Also read our Editorial Policy, How GMP is calculated, How allotment chances work, and IPO fund allocation.
Reviewed by
Dinesh Agrawal · Lead IPO Analyst
15+ years in Indian markets and IPO research. He reviews IPO dates and key details before they go live.